Skip to main content

Table 1 Clinical characteristics of the discovery and validation cohorts

From: Prognosis prediction model for conversion from mild cognitive impairment to Alzheimer’s disease created by integrative analysis of multi-omics data

Phenotype Factor All Discovery cohort Validation cohort
MCI-C Number of subjects 83 41 42
Age ± SD 75.22 ± 6.22 75.10 ± 5.64 75.33 ± 6.81
Percentage of male (# patients) 29 (24) 41 (17) 17 (7)
Number of APOE4 alleles (# patients) 0 (46), 1 (29), 2 (8) 0 (25), 1 (13), 2 (3) 0 (21), 1 (16), 2 (5)
Follow-up, mean ± SD (days) 927.18 ± 535.03 1014.07 ± 593.22 842.36 ± 462.90
MCI-NC Number of subjects 114 57 57
Age ± SD 75.56 ± 6.39 75.42 ± 5.75 75.70 ± 7.02
Percentage of male (# patients) 43 (49) 44 (25) 42 (24)
Number of APOE4 alleles (# patients) 0 (80), 1 (32), 2 (2) 0 (40), 1 (15), 2 (2) 0 (40), 1 (17), 2 (0)
Follow-up, mean ± SD (days) 1002.23 ± 564.49 939.70 ± 554.31 1064.75 ± 572.52
Total subjects 197 98 99
  1. MCI-C mild cognitive impairment converters (to Alzheimer’s disease), MCI-NC mild cognitive impairment non-converters, SD standard deviation